Patients who have heterozygous familial hypercholesterolemia (HeFH), a condition that causes abnormally raised low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease, ...
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial The study included CAR T-cell ...
Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
When Michael Linenberger, MD, retires from Fred Hutchinson Cancer Center at the end of 2022, his legacy will be felt by coworkers, trainees, patients and their families long after he has left the ...
An acute reduction in total cholesterol of ≥65%, or in LDL cholesterol of ≥70%, during each procedure; An interval mean total cholesterol of <7 mmol/l or LDL cholesterol <6.5 mmol/l (or decreases of ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
There is limited information on the pharmacotherapeutic management of children with homozygous FH from birth onwards, especially with regards to the initiation of drug treatment. However, clinicians ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results